The global acute lymphocytic leukemia therapeutics market size is estimated to register a considerable CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the rising initiatives undertaken by private & public organizations in the market.
Acute lymphocytic leukemia (ALL) is a malignancy that develops in the bone marrow from an early form of white blood cells termed lymphoblastic. The main cause of this type of cancer is an excess of malignant lymphoblast. The overproduction of malignant lymphoblast is characteristics of ALL. When a person has ALL, lymphoblast produces excessively and multiply in the bone marrow that cause damage to the bone marrow by inhibiting the generation of normal cells such as platelets and red blood cells (RBC). According to the American Cancer Institute, there were around 5,930 new cases of ALL had been detected in 2019, in which 3,280 cases were men and 2,650 cases were female. Furthermore, it is anticipated that the number of cases of ALL in Asia-Pacific and South American countries is anticipated to vary from 0.4 to 2 per 100,000 by 2020.
The COVID-19 pandemic has resulted in unforeseen consequences such as significant delays in disease detection and treatment. According to the Commonwealth Fund, COVID-19 is expected to result in nearly about 60% reduction in overall outpatient visits by the month of May 2020. On the other hand, hospitals and healthcare services were drastically curtailed owing to social distancing measures enacted by governments around the world. Furthermore, the pandemic had a significant impact on the functioning of hospital treatment for non-COVID-19 patients globally.
Market Trends, Drivers, Restraints, and Opportunities
- Increasing technological advancement in the healthcare sector and introducing new drugs by market leaders for the therapeutics methods are anticipated to fuel the growth of the market.
- Ongoing awareness programs conducted by private and public organization for the early diagnosis is one of the factors that propels the market growth.
- Stringent rules & regulations imposed by regulatory bodies for the approvals of therapeutics and the unwanted side effects of the drugs used in the therapy are likely to inhibit the growth of the market.
- Expiring patents of drugs used in the treatment and higher costs involved in the therapies are the potential restraints expected to hamper the market growth during the projected period.
- Rapid introduction of innovative therapies techniques and unmet potential demand for the treatment of the disease in emerging countries is expected to offer promising growth opportunities in coming future.
Scope of the Report
The report on the global acute lymphocytic leukemia therapeutics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
| Attributes | Details |
| Report Title | Acute Lymphocytic Leukemia Therapeutics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
| Base Year | 2020 |
| Historic Data | 2018–2019 |
| Forecast Period | 2021–2028 |
| Segmentation | Types (T-cell ALL, Precursor B-cell ALL, and Philadelphia Chromosome) and Therapies (Radiation Therapy, Targeted Therapy, Stem Cell Transplantation, and Chemotherapy [Nucleoside Metabolic Inhibitors, CALGB 8811 Regimen, Oncaspar, Linker Regimen, and Hyper-CVAD]) |
| Regional Scope | Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
| Report Coverage | Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
| Key Players Covered in the Report | Genzyme Corp.; Spectrum Pharmaceuticals Inc.; Pfizer Inc.; Sigma-Tau S.p.A.; and Erytech Pharma S.A |
Market Segment Insights
Precursor B-ALL segment is expected to expand at a rapid pace
Based on types, the global acute lymphocytic leukemia therapeutics market is segmented into T-cell ALL, precursor B-cell ALL, and Philadelphia chromosome. The precursor B-ALL segment is expected to expand at a rapid pace in the coming years attributing to the increasing cases of this condition in adults. As per the National Comprehensive Cancer Network (NCCN) research, the B-cell ALL subtype begins in young cells that form in bone marrow and eventually mature into mature B-cells (B-lymphocytes), resulting in Burkitt type ALL (mature B-ALL). It is the most prevalent form of ALL subtype. BCR-ABL gene and mature B-cell ALL are two types of precursor B-cell ALL (Burkitt type). Tyrosine kinase inhibitors including dasatinib (Sprycel), imatinib (Glivec), and nilotinib are commonly used to treat ALL (Tasigna). Acute lymphoblastic leukaemia is one of the indications for the medication described above.
Chemotherapy segment is projected to account for a key market share
On the basis of therapies, the market is segregated as radiation therapy, targeted therapy, stem cell transplantation, and chemotherapy. The chemotherapy segment is further segmented into nucleoside metabolic inhibitors, CALGB 8811 regimen, oncaspar, linker regimen, and hyper-CVAD. The chemotherapy segment is projected to account for a key market share during the forecast period. The growth of the market is attributed to the capability of destroying leukemia cells and prevent multiplication of cancerous cells that slow down the progress of disease. Single or combination medications, as part of chemotherapy regimen, are used to treat lymphocytic leukemia in chemotherapy. Cytotoxic agents, antimetabolites, alkylating compounds, and other plant derivatives are all used in this therapy. Furthermore, stem cell transplantation can be combined with chemotherapy, allowing healthcare providers to administer high-dose chemotherapy infusions for effective treatment.
On the other hand, the targeted therapy is estimated to fuel the segment during the forecast period. In comparison to chemotherapy, this therapy provides advantages such as greater therapeutic precision and efficiency as well as faster recovery. Furthermore, increased demand for tailored medicines for the treatment of this disorder is one of the factors propelling the segment in the market.
North America is anticipated to constitute a key market share
In terms of regions, the global acute lymphocytic leukemia therapeutics market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key market share during the forecast period. The market growth of the region is attributed to the robust healthcare infrastructure, early launch of various improved drugs, such as besponsa (inotuzumab ozogamicin), and availability of strong product portfolio in the market.
Meanwhile, the market of Asia Pacific is projected to expand at a substantial growth rate during the forecast period attributing to the increasing demand for clinical needs, availability of effective & safe treatment, rising disposable income, and ongoing awareness campaigns regarding early diagnosis in emerging countries such as India and China.
Segments
Segments Covered in the Report
The global acute lymphocytic leukemia therapeutics market has been segmented on the basis of
Types
- T-cell ALL
- Precursor B-cell ALL
- Philadelphia Chromosome
Therapies
- Radiation Therapy
- Targeted Therapy
- Stem Cell Transplantation
- Chemotherapy
- Nucleoside Metabolic Inhibitors,
- CALGB 8811 Regimen
- Oncaspar
- Linker Regimen
- Hyper-CVAD
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Genzyme Corp.
- Spectrum Pharmaceuticals Inc.
- Pfizer Inc.
- Sigma-Tau Industrie Farmaceutiche Riunite S.p.A.
- Erytech Pharma S.A
Competitive Landscape
Some of the major players competing in the market are Genzyme Corp.; Spectrum Pharmaceuticals Inc.; Pfizer Inc.; Sigma-Tau S.p.A.; and Erytech Pharma S.A. These major players are implementing various marketing strategies such as capital investments, merger & acquisitions, and new product development to enhance their position in the market.
For example, in June 2015, Celgene Corporation had announced a partnership with Juno Therapeutics with a target to develop and commercialize immunotherapies for cancer and autoimmune diseases. Amgen Inc., as a major biotechnology firm, develops, manufactures, and distributes pharmaceuticals for severe illnesses. The company has offered several development in human therapeutics, with a focus on developing innovative medications based on cellular and molecular biology developments. Furthermore, in January 2019, the European Commission had approval to Amgen Inc. for the development of blinatumomab monotherapy. It was aimed to help in the treatment of adult patient group that are suffering from Philadelphia chromosome negative (Ph-) CD19 positive B-cell precursor ALL.
Request For Customization
Enquiry Before Buying
Speak With Analyst
